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doi:10.1016/j.jtcvs.2006.06.021bjectives: Previous studies of aprotinin use in thoracic aortic surgery, limited in
ize and design, reported minimal information regarding outcomes other than blood
oss and transfusion. The evaluation of impact of aprotinin on surgical outcomes in
large sample is needed.
ethods: Patients at Yale New Haven Hospital undergoing thoracic aortic surgery
aneurysm repair, dissections, penetrating ulcers, intramural hematomas) between
995 and 2003 were considered for inclusion. Each patient receiving aprotinin was
atched to a control per preoperative profile (age, gender, urgency of surgery,
issection/location of aortic disease). Data (surgical specifics, demographic vari-
bles, comorbidities, disease location-related variables, preoperative medications,
ntraoperative medications, surgical/operative data) were abstracted from the
ecords of successfully matched aprotinin-treated patients and controls (n  168).
omparison and determination of success of matching were performed using
ivariate analyses. Outcome variables were compared using statistical tests for
aired data. Supplementary unpaired and regression analyses were also performed.
esults: Baseline demographics of groups were similar, although controls had
educed history of aortic disease, but greater intraoperative use of lysine analogs (P
.05). Aprotinin significantly reduced platelet transfusion (P  .05). Paired
ivariate analyses showed a tendency toward reduced ventilation time, pulmonary
omplications, and permanent arrhythmias (P  .05) associated with aprotinin.
upplementary analyses were supportive only for pulmonary complications and
ermanent arrhythmias.
onclusions: The current evaluation substantiates previous reports that aprotinin
ay be safe to use and likely to improve some outcomes of thoracic aortic surgery.
owever, further studies for rare safety and efficacy end points are warranted.
horacic aortic surgery with or without deep hypothermic arrest is associated
with altered hemostasis that results in increased postoperative bleedin1,2
The surgery is also associated with high rates of stroke and morta3,4
ultiple factors may be associated with these events: extensive surgical stress, need
or complete inhibition of coagulation process, hemodilution, ischemia, and
eperfusion.
Aprotinin (Trasylol, Bayer Pharmaceuticals Corp, West Haven, Conn) is a
road-spectrum, nonspecific serine protease inhibitor that has been shown to be
ssociated with reduced inflammatory response and organ-protective effect5-7
echanisms for these beneficial effects include decrease in fibrinolysis, inhibition
f neutrophil activation, preservation of platelet membranes, and inhibition of
allikrein.8-10 Aprotinin is also known for its ability to reduce blood loss and
ransfusion requirements in cardiac surgery.11-13 However, the safety and efficacy 
horacic aortic surgery are still considered controversial. Two small studies in
The Journal of Thoracic and Cardiovascular Surgery ● Volume 132, Number 4 909
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9
CSPhoracic aortic surgery have reported that aprotinin is not
ssociated with a reduction in blood loss14,15 and that it 
ssociated with renal dysfunction.14,15 Another large study
id not support renal failure concerns related to aprotinin
ut also did not report reduction in blood transfusion in
atients undergoing operation with the deep hypothermia
echnique.16 Conversely, recent studies reported a benefic
ffect of aprotinin on blood transfusion requirements and
lso dismissed safety concerns related to aprotinin in tho-
acic aortic surgery with or without deep hypothermia.17-19
ost previous studies were limited in size, design, and
ollow-up evaluations. In addition, they reported little in-
ormation about outcomes of the surgery other than blood
ransfusion. Accordingly, the primary goal of the current
tudy is to determine whether the use of aprotinin is asso-
iated with improved outcomes of surgery including, but
ot limited to, reduction in blood transfusion requirements.
atients and Methods
ore than 380 patients underwent thoracic aortic surgery at Yale
ew Haven Hospital by the end of 2003. All patients undergoing
urgery for aneurysm repair, dissections, penetrating ulcers, and
ntramural hematomas were considered for inclusion in the study.
iven the use of aprotinin in high-risk patients and sample-size
imitations, each patient receiving aprotinin was matched to a
ontrol. Matching was performed on the basis of an electronic data
ource that captured preoperative profiles of the patients (M. T.,
. S.). The sample included patients who underwent surgery
etween 1995 and 2003. However, more than 90% (n  152) of
he patients underwent surgery after 1999. Matching variables
ncluded age (2 years), gender, urgency of surgery (urgent,
mergency, elective), deep hypothermic cardiac arrest (DHCA)
se, time/year of the surgery (1 year), dissection, and location of
ortic disease (ascending, arch, descending). Successful matching
as achieved for 84 patients receiving aprotinin. Overall, 168
atients were included in the study, and detailed clinical and
onclinical information were abstracted from medical records for
ll patients by an experienced cardiothoracic nurse (M. T.). The
tudy was approved by the Yale University School of Medicine
uman Investigations Committee.
urgical Specifics
n most cases cerebral protection was performed by DHCA. Ret-
ograde brain perfusion was not used in these patients. Carbon
ioxide flooding of the field was used for all recent operations to
Abbreviations and Acronyms
ACT  activated clotting time
CABG  coronary artery bypass graft
ECM  extracellular matrix
DHCA deep hypothermic cardiac arrest
KIU  kallikrein inactivation unitrevent air embolism. In addition, cerebrospinal fluid drainage was p
10 The Journal of Thoracic and Cardiovascular Surgery ● Octosed for descending thoracic aortic operations. Only full-dose
protinin (full Hammersmith dose: 2 million kallikrein inactivation
nits [KIU] intravenously, 2 million KIU pump prime, and 0.5
illion KIU/h continuous infusion) was used unless there was a
ajor renal impairment. Activated clotting time (ACT) monitoring
as based on kaolin, and an ACT of 500 seconds was considered
dequate. There was no strict protocol on infusion of aprotinin
uring circulatory arrest because the drug was discontinued by
ome anesthesiologists and continued by others.
tudy Variables
emographic variables included age, gender, race, body mass
ndex, and body surface area. Comorbidities included family his-
ory of aortic disease, smoking status, diabetes, history of renal
isease, hypertension, cerebrovascular disease, peripheral vascular
isease, chronic obstructive pulmonary disease, coronary heart
isease, obesity, New York Heart Association functional class, and
reoperative arrhythmia (mostly atrial fibrillation). Disease loca-
ion-related variables were lesion location (ascending, arch de-
cending), aortic stenosis, aortic insufficiency, previous vascular/
ardiac surgery, and ejection fraction.
Preoperative medication data included beta-blocker, calcium
hannel blocker, angiotensin-converting enzyme inhibitor, and as-
irin or clopidogrel use. Intraoperative medications included ami-
ocaproic acid/tranexamic acid, Hetastarch (Sigma-Aldrich, St
ouis, Mo), albumin, and fibrin glue. Surgery-related data in-
luded aortic dissection, preoperative shock, urgent or emergency
urgery, cardiac catheterization, preoperative hemoglobin, and pre-
perative hematocrit. Operative data included cardiopulmonary
ypass time, crossclamp time, circulatory arrest time when DHCA
as used, use of blood cardioplegia, coronary artery bypass graft
CABG) surgery, and valve surgery. Continuous outcomes in-
luded 24-hour drainage, packed red blood cells, fresh frozen
lasma, platelet use, hemoglobin (on day 1), hematocrit (on day 1),
otal ventilation time, total intensive care unit time, and total length
f stay. Dichotomous outcomes included embolism, myocardial
nfarction, stroke, transient cerebrovascular accident, renal failure,
ulmonary complications, infection, arrhythmia, permanent ar-
hythmia, mortality, combined end point of stroke myocardial
nfarction or mortality, any complication (embolism, myocardial
nfarction, stroke, renal failure, pulmonary complication, perma-
ent arrhythmia, or death), and length of stay more than 7 days.
tatistical Analysis
n the first step of the analyses, descriptive statistics for study
ariables were calculated. Then, bivariate analyses were per-
ormed to compare characteristics of patients receiving aprotinin
ith those of controls and to determine the success of matching.
he t test was used to compare the groups with regard to contin-
ous variables. The chi-square test was used to compare the groups
ith regard to dichotomous outcomes. If sample size requirements
or chi-square were not met, the Fisher exact test was used to
ompare the groups. In the third stage of the analyses, aprotinin
ecipients and controls were compared regarding outcome vari-
bles. Because of matching performed in pairs, we used the paired
test for continuous outcomes such as red blood cells, fresh frozen
lasma, platelet transfusion, and other variables.
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CS
PThe McNemar test was used for dichotomous outcomes such as
ccurrence of death, stroke, atrial fibrillation, and other variables.
n these analyses 84 pairs were available that were separated into
oncordant and discordant pairs (Table 4). AQ Test statistics 
ased on discordant pairs, and odds ratios were calculated. Con-
dence interval (95%) calculations for odds ratios are based on
xact binomial distribution.
These analyses were supplemented (Appendixes 1–3) with
nmatched analyses and regression analyses to provide supple-
entary information. We used the Statistical Analysis System
SAS Institute, release 8.02, Cary, NC) and STATA statistical
oftware (release 8.0, College Station, Tex) for data management
nd analysis.
esults
he mean age of patients was 61.7 years, and 38.1% were
emale. Those with ascending aortic disease constituted the
ajority of the patients (Table 1), and aortic dissection
bserved in 36% of patients (Table 2). Matching pat
eceiving aprotinin with control patients was successful
TABLE 1. Baseline demographics, comorbidities, and dise
Variables
Baseline demographics Age (mean  SD) y
Body mass index (mean 
Body surface area (mean 
Female gender
Race
White
Black
Hispanic
Other
Comorbid conditions Family history of aortic dise
Current smoker
Diabetes
History of renal failure
Hypertension
Cerebrovascular disease
Peripheral vascular disease
COPD
Coronary heart disease
Obesity (BMI 30)
NYHA class (III-IV)
Preoperative arrhythmia*
Disease-related
variables
Location
Ascending
Arch
Descending
Aortic stenosis
Aortic insufficiency
Previous cardiac/vascular s
COPD, Chronic obstructive pulmonary disease; BMI, body mass index; NYH
†P  .05 between the groups.ith only a few differences between the groups. Patients c
The Journal of Thoracics
eceiving aprotinin were more likely to have a family his-
ory of aortic disease compared with controls (Table 1)
ontrols were more likely to receive antifibrinolytics (epsi-
on aminocaproic acid [Amicar, Amgen Inc, Thousand
aks, Calif]AQ or tranexamic acid) (Table 2). Thus, a
inin in this study was essentially compared with an alter-
ative blood loss reduction strategy that included antifi-
rinolytic therapy more than 50% of the time.
In paired data analyses, aprotinin recipients received
ewer platelets (on average 0.6 packs per person; 4 units
ithin each pack) and had a shorter ventilation period in the
ntensive care unit (mean difference 13 hours) (Table
upplementary unpaired analysis did not provide strong
tatistically significant evidence for reduced ventilation
ime, although a tendency toward reduced time on the
entilator was still apparent. Reduction in platelet require-
ents was robust in both analyses. There was evidence for
substantial reduction in 24-hour drainage in patients re-
specific variables in treatment groups
Aprotinin (n  84) Control (n  84)
61.6  15.7 61.7  15.3
26.7  5.5 26.2  4.3
1.9  0.3 1.9  0.2
38.1% 38.1%
83.3% 92.8%
10.7% 1.2%
4.8% 3.6%
1.2% 2.4%
51.5% 33.3%†
25.0% 33.0%
6.0% 9.5%
6.0% 1.2%
79.8% 66.7%
7.1% 8.3%
7.1% 8.3%
11.9% 15.5%
17.9% 23.8%
27.4% 19.7%
20.3% 32.1%
15.5% 8.3%
83.3% 83.3%
4.8% 3.6%
11.9% 13.1%
3.6% 11.9%
48.8% 36.9%
ry 14.3% 9.5%
w York Heart Association; SD, standard deviation. *Mostly atrial fibrillation.ase-
SD)
SD)
ase
urge
A, Neeiving aprotinin (Appendix 1).
and Cardiovascular Surgery ● Volume 132, Number 4 911
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9
CSPPaired data analyses for dichotomous outcomes have
hown fewer pulmonary complications and permanent ar-
hythmias with aprotinin use (Table 4). A strong tend
oward reduction in the outcome defined as any complica-
ion (see “Study Variables”) was also observed. Supplemen-
ary unpaired analyses also provided evidence for reduced
ulmonary complications and a strong tendency toward
eduction in permanent arrhythmias (Appendix 2). No other
tatistically significant associations were found.
Supplementary multivariable regression models pro-
ided evidence for reduced occurrence of permanent ar-
hythmias and reduced requirements for platelets (Appendix
). Similarly, there was a strong tendency toward reduction
f pulmonary complications and total ventilation. The ten-
ency toward reduction in any complication was less robust
n these analyses.
iscussion
ven in the hands of experienced surgeons, thoracic aortic
urgery is associated with significant morbidity and mortal-
ty.20 The current evaluation shows that aprotinin use
horacic aortic surgery is likely to be associated with some
mproved outcomes in this setting. The most robust obser-
ations were substantial reductions in platelet requirements.
owever, it is still possible that platelets were used as part
ABLE 2. Preoperative medications and operative variable
Variables
edications Preoperative
Beta-blocker use
Calcium channel use
ACE inhibitor use
Aspirin or clopidogrel use
Intraoperative
Aminocaproic acid/tranexam
Hetastarch use (vs albumin)
Fibrin glue use
urgery-related data Aortic dissection
Preoperative shock
Urgent or emergency surgery
Ejection fraction (50%)
Cardiac catheterization
Preoperative hemoglobin (mean
Preoperative hematocrit (mean
perating room data CPB (mean  SD) min
Crossclamp (mean  SD) min
Circulatory arrest (mean  SD)
DHCA used
CABG performed
Valve replaced
Blood cardioplegia
CE, Angiotensin-converting enzyme; CPB, cardiopulmonary bypass; DHCA
rtery bypass grafting. *For patients undergoing DHCA only. †P  .05 bef the prophylactic intervention rather than a measure to (
12 The Journal of Thoracic and Cardiovascular Surgery ● Octoeduce bleeding (outcome). There was also reduction in
ermanent arrhythmia and possibly pulmonary complica-
ions. There is some evidence for reduced 24-hour drainage
n the subset of 113 patients in the supplementary analyses.
the treatment groups
Aprotinin (n  84) Control (n  84)
59.1% 53.5%
34.3% 31.2%
36.9% 27.4%
51.4% 49.4%
id 4.9% 56.8%†
20.2% 16.7%
66.7% 70.2%
36.9% 35.7%
9.5% 11.9%
41.7% 45.2%
16.7% 17.9%
20.2% 22.6%
D) 13.2  2 13.5  2
D) 39.6  6.4 39.4  7.1
145.2  38.3 143.7  52.2
83.7  34.3 86.0  49.9
25.5  15.1 22.9  15.5
67.9% 64.3%
9.5% 17.8%
40.5% 39.1%
22.7% 18.9%
p hypothermic circulatory arrest; SD, standard deviation; CABG, coronary
the groups.
ABLE 3. Paired analysis of aprotinin and continuous clin-
cal outcomes
utcomes
Aprotinin–control
(paired) P* P†
ed blood cell transfusion
(packs)
0.6  5.1 .2 .6
FP transfusion (packs) 0.5  5.3 .3 .5
latelets transfusion (packs)‡ 0.6  2.1 .021 .022
emoglobin (d 1) 0.25 1.9 .2 .2
ematocrit (d 1) 1.0 5.4 .1 .1
otal ventilation (h) 13.8 56.1 .029 .023
otal ICU stay (h) 14.7 258.3 .6 .2
otal LOS (d) 4.2 41.6 .4 .8
FP, Fresh frozen plasma; ICU, intensive care unit; LOS, length of stay.
eans  standard deviation presented for the difference between apro-
inin and control groups in pairs. Minus sign indicates reduction in the
uantity relative to control when aprotinin used; absence of minus sign
ndicates increase relative to control when aprotinin used. *Paired t test
sed for statistical analyses based on 84 pairs. †Wilcoxon signed-rank test
esults based on 84 pairs. ‡Each platelet pack contained 4 units of plateletss in
ic ac
 S
 S
min*
, deestandard multidonor).
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CS
Pimitations related to missing data did not permit more
omplete analysis of this outcome. Overall, aprotinin recip-
ents tended to have fewer complications, although statisti-
ally significant improvements for rare outcomes such as
troke and mortality were not observed.
Aprotinin is known to reduce blood loss and blood
ransfusion requirements in CABG and cardiac surgery in
eneral.11,12,21 However, efficacy and safety data publish
or use in thoracic aortic surgery and deep hypothermic
irculatory arrest (Table 5) have been both positive17-19 and
egative.14-16 The current analysis, in patients undergoi
horacic aortic surgery with and without deep hypothermic
rrest, provides level II evidence that aprotinin is likely safe
o use and possibly reduces blood loss and transfusion
equirements in this population.
Prospective, randomized, controlled data evaluating aproti-
in use in CABG surgery show no significant adverse impact
n renal function,11 although reports in thoracic aortic surge
ndicate adverse,14,15 transient,18,19 or no16,17 effects on thi
arameter. In the current analysis, aprotinin recipients at base-
ine trended toward an increase in history of renal failure.
espite this baseline, aprotinin recipients showed no increase
n this outcome compared with controls (odds ratio, 0.33; P
3). However, large confidence intervals (0.01-4.15) around the
isk estimate do not exclude this possibility. Because aprotinin
as been shown to artificially prolong ACT values, maintain-
ng adequate heparinization is important,17 particularly in pro-
edures with deep hypothermic arrest. Critical evaluation of
ABLE 4. Paired analysis of aprotinin and dichotomous cl
ichotomous outcomes
Concordant
A  0/C  0
Discordant
A  1/C  0
mbolism 69 6
yocardial infarction 80 0
troke 74 3
CVA 67 5
enal failure 77 1
ulmonary
complications
62 5
nfection 77 4
rrhythmia 28 11
ermanent
arrhythmia
61 6
ombined end point† 62 8
ny complication‡ 37 13
eath 73 3
OS (7 d) 9 8
R, Odds ratio; TCVA, transient cerebrovascular accident; LOS, length of s
/C  0 defines pairs where no outcome events occurred; A  1/C  0
n the control; A  0/C  1 defines pairs where outcome event did not oc
airs where outcome event occurred in both aprotinin and control recip
Includes any of the following: embolism, myocardial infarction, stroke, rehis issue suggests that excessive mortality and complication t
The Journal of Thoracicates, including renal dysfunction, have been reported when the
dequacy of anticoagulation is questionable.22 Minimal target
CT values of 600 to 1000 seconds have been used to monitor
eparinization,18,22,23 as well as maintaining heparin lev
reater than 2.7 to 3.5 U/kg.16,22 In our study, kaolin-base
onitoring and an ACT of 500 or greater were used.
The current evaluation in thoracic aortic surgery shows that
protinin therapy is associated with a reduction in arrhythmias.
hese data are aligned with those of a recent meta-analysis of
ABG studies showing a trend in reduced atrial fibrillation
ates for those patients treated with aprotinin.11 Alternatively,
ample-size limitations do not exclude the possibility of this
enefit occurring by chance alone. A mechanism for this
ossible effect is unclear, although animal models show that
protinin reduces myocardial ischemia-reperfusion injury,24-26
nd ischemia-reperfusion injury is associated with mitochon-
rial dysfunction and subsequent atrial fibrillation in patients
ndergoing cardiac surgery.27 Concurrently, reduction in plate-
et transfusion may have a beneficial impact on this parameter
n patients undergoing cardiac surgery.28 Further evaluation o
his possible effect is warranted, because perioperative arrhyth-
ias increase resource use and costs in the cardiac setting.
Our analysis indicates that aprotinin therapy may be
ssociated with improved pulmonary outcomes. Previous
tudies have reported improvement on various pulmonary
arameters in patients treated with aprotinin relative to
ontrols, including mean airway pressures and Pa[scap-
co[r]2 levels,29 alveolar-arterial oxygen gradients,30,31 and
l outcomes
oncordant
 1/C  1
Discordant
A  0/C  1 P* OR
1 5 .8 1.20 (0.31-4.97)
0 2 — —
0 4 .7 0.75 (0.11-4.43)
0 9 .3 0.56 (0.15-1.85)
1 3 .3 0.33 (0.01-4.15)
2 14 .039 0.36 (0.10-1.05)
0 3 .7 1.33 (0.23-9.10)
26 19 .1 0.58 (0.25-1.28)
2 15 .049 0.40 (0.13-1.09)
1 13 .3 0.62 (0.22-1.60)
9 25 .051 0.52 (0.24-1.06)
0 6 .3 0.50 (0.08-2.34)
31 10 .6 0.80 (0.27-2.25)
McNemar test for dichotomous paired data; A, aprotinin; C, control. A 
s pairs where outcome event occurred in the aprotinin recipient but not
the aprotinin recipient but did occur in the control; A  1/C  1 defines
. †Combined end point includes myocardial infarction, stroke, or death.
ilure, pulmonary complication, permanent arrhythmia, or death.inica
C
A
tay. *
define
cur in
ientsime on ventilation.32,33 An impact on pulmonary function
and Cardiovascular Surgery ● Volume 132, Number 4 913
TABLE 5. Summary of literature on aprotinin use in deep hypothermic circulatory arrest
Author, year Study design (n) Anticoagulation Efficacy Safety
Mora Mangano et al, 200116 Retrospective (44 aprotinin
full dose; 139 control)
Heparin to maintain levels
3.5-4.0 /kg using
Hepcon system
Aprotinin group received more
(P  .05) blood products
intraoperatively (platelets, 10
vs 6.6 U; FFP, 4.8 vs 3.1 U,
cryo, 9.9 vs 5.4 U) and
postoperatively (cryo, 7.3 vs
3.0 U)
Aprotinin did not increase likelihood
of postoperative renal dysfunction
(aprotinin, 39%; control 38%)
Seigne et al, 200039 Retrospective (9 aprotinin
half dose; 10 control)
Heparin 300 U/kg load
plus 100 /kg for Celite
ACT 480 s for control
(mean, 846 s) and
kaolin ACT 650 s for
aprotinin (mean, 864 s);
reversal with protamine
3 mg/kg initially then 1
mg/kg to baseline
Aprotinin group received
fewer (P  .05) blood
products (RBC 1.3 vs 4.5
U/patient; FFP 1.3 vs 5.7 U;
platelets 0.5 vs 3.5 U)
Renal failure or MI did not develop
in any patient during first 5 days
postoperatively; 2 control patients
had chronic seizures; 1 patient
taking aprotinin had stroke and
died
Ehrlich et al, 199819 Prospective, randomized
(25 aprotinin low dose;
25 placebo)
Heparin 3 mg/kg for
kaolin ACT mean, 825-
965 s; aprotinin mean,
873 s; control mean,
823 s
Aprotinin group postop
received fewer (P  .05)
blood products (RBC 1.2 vs
3.5 U; other products 2.4 vs
5.1 U) and had reduced (P
 .05) chest tube output
(717 vs 920 mL)
No significant differences using
specific assessment of renal
function; no differences in
complications (aprotinin vs
placebo, respectively, reversible
neurologic deficit, 1 vs 2; stroke,
0 vs 1; MI, 0 vs 1; renal
dysfunction, 2 vs 1; RF, 2 vs 1;
30 d mortality, 3 vs 4)
Parolari et al, 199740 Retrospective (18 aprotinin
full dose; 21 control)
Heparin 300 /kg load,
plus 100 /kg for Celite
ACT 800 s in aprotinin
group and 440 s in
control; protamine
reversal 1:1; aprotinin
mean, 1028 s; control
mean, 619 s
No significant difference in
postoperative blood loss
(aprotinin, 1213 mL; control,
1528 mL) and donor blood
transfused (aprotinin, 9.4 U;
control, 9.9 U)
Some differences in complications
(aprotinin vs control, respectively,
in-hospital mortality, 28% vs 29%,
MI, 11% vs 0%; RF, 17% vs 10%,
neurologic deficit, 28% vs 5%;
composite complicated
postoperative course, 45% vs
19%); in regression analysis
aprotinin predictor of complicated
course
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TABLE 5. Continued
Okita et al, 199717 Consecutive, prospective
(94 aprotinin low dose)
All received heparin 3
mg/kg before CPB;
Group A (n  49) given
heparin irrespective of
ACT (1 mg/kg/h); Group
B (n  45) given
heparin (1 mg/kg/h)
when kaolin ACT
500 s
No significant difference in
bleeding; Group A showed
better preservation of
platelets and reduced
activation of coagulation
No significant differences (P  .05)
in complications (A vs B,
respectively, mortality, 6 vs 4;
stroke, 2 vs 1; RF, 1 vs 1; MI, 2 vs
2, bleeding 6 vs 4; reexploration
for bleeding, 4 vs 2; DIC, 0 vs 1)
Goldstein et al, 199518 Retrospective (24 aprotinin
full dose; 24 control)
Target ACT (kaolin, 500 s;
Celite, 750 s); mean
ACT during CPB
different (aprotinin,
1073 s; control, 681 s; P
 .05)
No difference in intraoperative
blood products or chest
tube output; aprotinin group
postoperatively received
fewer RBCs (1.3 vs 3.2 U, P
 .05) and decreases (NS)
in other products (2.2 vs
6.5), patients receiving no
transfusion (16.7% vs 4.1%),
and patients receiving 10
U of blood products (45.8%
vs 12.5%)
No significant differences in
adverse events (aprotinin vs
control, respectively, seizures, 0%
vs 4.2%; reversible neurologic
deficit, 4.2% vs 4.2%; stroke,
12.5% vs 12.5%; MI, 0% vs 8.3%;
dialysis, 8.3% vs 8.3%; elevated
serum creatinine, 29.2% vs 8.3%;
in-hospital death, 8.3% vs 29.2%)
Westaby et al, 199415 Retrospective (38) and
prospective (42); (53
aprotinin full dose; 27
control)
ACT initially 400 s but
later 700 s for
patients receiving
aprotinin; control ACT
400 s
Blood loss and transfusion
requirements consistently
higher (NS) in aprotinin
group over 6-year period
Return to surgery for bleeding
occurred more frequently in
aprotinin group (11% vs 0%);
mortality rates similar (5 per
group)
Sundt et al, 199314 Retrospective (20 aprotinin
full dose; 20 control)
Heparin 250-350 /kg and
2000-5000 U in pump
prime for ACT 480 s;
protamine reversal 1.3
mg/100 U; aprotinin
lowest mean, 777 s;
control lowest mean,
635 s
No significant differences in
blood product use or chest
tube output
Patients treated with aprotinin
showed significantly (P  .05)
increased rates of renal
dysfunction (65% vs 5%), RF 25%
vs 0%, and hospital mortality
(35% vs 5%) and elevated (NS)
rates of reoperation for bleeding
(15% vs 0%), MI (20% vs 5%), and
stroke (15% vs 5%)
ACT, Activated clotting time; aprotinin full dose, aprotinin 2 million KIU load, 2 million KIU pump prime, and 0.5 million KIU/h infusion; aprotinin half dose, aprotinin 1 million KIU load, 1 million KIU pump
prime, and 0.25 million KIU/h infusion; aprotinin low dose, aprotinin dose less than half dose; cryo, cryoprecipitate; FFP, fresh frozen plasma; MI, myocardial infarction; NS, not significant; RBC, red blood
cell; RF, renal failure; DIC, diffuse intravascular coagulation.
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CSPay mechanistically be associated with reduced systemic
nflammatory effects,5-7 although the effect of aprotinin 
ignificantly reduce platelet transfusion may also have a role
n improvements in this parameter.28
In patients undergoing thoracic aortic surgery, rates of
troke (descending aorta, 5%; ascending aorta, 8%) and death
descending and thoracoabdominal aortas, 8%; ascending and
rch, 2.5%) are relatively high compared with other cardiac
rocedures.20 Meta-analyses have shown that in CABG s-
ery, aprotinin therapy is associated with a reduction in stroke
ith no apparent effect on mortality,11 whereas across differen
ardiac surgeries (CABG and valve combined) aprotinin seems
o be associated with reduced mortality.12 Conversely, several
necdotal reports of fatal thrombosis in hypothermic circula-
ory arrest with the use of aprotinin,34-37 as well as the use 
ntifibrinolytic aminocaproic acid,38 exist in the literatur
hese case series merit consideration and further data collec-
ion effort in the future. In the current evaluation in thoracic
ortic surgery, although the sample size was reasonably large,
ower limitations were observed in determination of possible
ifferences in stroke, transient cerebrovascular accident, fatal
hrombosis, and mortality.
We believe that the current evaluation of a large cohort
f carefully matched patients who underwent thoracic aortic
urgery at a major teaching hospital has added more evi-
ence to the safety and efficacy of aprotinin in this setting.
hese data substantiate previous reports that aprotinin can
e safe and possibly improve some outcomes in thoracic
ortic surgery. Further studies for rare safety and efficacy
nd points are warranted.
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PPPENDIX 1. Unpaired analysis for continuous clinical
utcomes
utcomes Aprotinin Control P* P†
4-h drainage‡ 567.0 259.8 717.4 424.3 .022 .1
ed blood cell transfusion
(packs)
2.5  3.6 3.2 4.4 .3 .3
FP transfusion (packs) 2.4 2.6 2.9 4.9 .4 .9
latelet transfusion
(packs)
0.9  1.3 1.5 1.8 .025 .026
emoglobin (d 1) 10.6 1.3 10.3 1.4 .2 .3
ematocrit (d 1) 31.3 3.7 30.3 4.0 .1 .2
otal ventilation (h) 29.1 57.8 51.3 109.5 .1 .035
otal ICU stay (h) 109.0 249.5 122.8 192.6 .7 .2
otal LOS (days) 15.4 39.0 11.2 13.7 .3 .9
FP, Fresh frozen plasma; ICU, intensive care unit; LOS, length of stay. *T
est for unmatched analysis for 168 patients. †Wilcoxon 2-sample test
esults based on 168 patients. ‡Data available for 113 patients. t
The Journal of ThoracicPPENDIX 2. Unpaired analysis for dichotomous clinical
utcomes
utcomes
Aprotinin
n  84
Control
n  84 P*
mbolism (%) 8.4 8.5 1.0
yocardial infarction (%) 0 2.4 .5
troke (%) 3.6 6.1 .5
CVA (%) 6.0 11.1 .2
enal failure (%) 2.4 6.0 .4
ulmonary complications (%) 8.4 19.3 .043
nfection (%) 4.8 3.6 1.0
rrhythmia (%) 46.4 52.4 .4
ermanent arrhythmia (%) 9.5 19.0 .078
ombined end point† (%) 7.1 11.9 .3
ny complication‡ (%) 23.8 34.5 .1
eath (%) 4.8 8.4 .3
OS (7 d) (%) 63.1 63.1 1.0
CVA, transient cerebrovascular accident; LOS, length of stay. *Chi-square
est or Fisher exact test (if cell counts 5) used in analyses. †Combined
nd point includes myocardial infarction, stroke, or death. ‡Includes any of
he following: embolism, myocardial infarction, stroke, renal failure, pul-PPENDIX 3. Unconditional multivariable analyses for se-
ected outcomes
ichotomous outcomes OR
ulmonary complications* 0.40 (0.15-1.07)
ermanent arrhythmia* 0.38 (0.15-0.98)
ny complication† 0.59 (0.30-1.16)
ontinuous outcomes
Difference (aprotinin-control)
(95% CI)**
latelets transfusion (packs)‡ 0.6 (1.1-0.1)
otal ventilation (h)* 21.2 (48.2-5.7)
R, Odds ratio. *Adjustment performed for preoperative status (chronic
bstructive pulmonary disease for pulmonary complications and total
entilation and preoperative arrhythmia for permanent arrhythmia). †In-
ludes any of the following: embolism, myocardial infarction, stroke, renal
ailure, pulmonary complication, permanent arrhythmia, or death. No ad-
ustment was performed because of heterogeneity of outcomes. ‡Adjust-
ent performed for cardiopulmonary bypass time, crossclamp time, pre-
perative hemoglobin, and preoperative hematocrit. **For continuous
utcomes, minus sign indicates reduction associated with aprotinin rela-ive to control.
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